Eli Lilly stock price forecast: $1,170 resistance as LLY gains 5.49%

Traders Union
All News
Financial News
Eli Lilly surges 5.49% to $1,142.36

Highlights

Eli Lilly's early positive data from the VERVE-102 cholesterol trial signals pipeline momentum and boosts expectations for coming milestones.
Strategic acquisitions and the LillyDirect launch aim to diversify the infectious disease portfolio and accelerate weight loss drug adoption.
Shares exhibit strong bullish momentum with overbought signals; trading is expected between $1,100 and $1,170 over the next five days.

Pipeline advances and acquisitions drive outlook amid strategic expansion

Eli Lilly has reported encouraging early Phase 1b results from its VERVE-102 cholesterol trial, signaling tangible progress in its pipeline and fostering expectations for future clinical and commercial milestones. In parallel, the company is broadening its R&D footprint through agreements to acquire Curevo Inc., LimmaTech Biologics AG, and Vaccine Company, Inc., which is expected to diversify its infectious disease portfolio and expand long-term growth opportunities. The recent launch of LillyDirect, enabling Zepbound prescription delivery via telehealth, demonstrates a strategic push toward increased patient access and could accelerate uptake in the high-demand weight loss drug segment. Ongoing plans to launch new drugs internationally, despite regulatory pricing pressures, further highlight operational momentum and support strong investor demand.

Overbought risk builds as bullish momentum pushes past resistance

The current price is significantly above the SMA-20 at $994.04, the SMA-50 at $946.74, and the SMA-200 at $932.63. The Ichimoku Kijun (D1) level stands at $971.75, which now acts as immediate technical support. Momentum indicators show robust readings: MACD remains bullish, ADX is neutral yet steady, and the Awesome Oscillator supports the ongoing upward trend. However, oscillators such as RSI (70.58), Stoch RSI (100), and CCI (163.92) signal heavily overbought conditions, while the BBP indicates strong buyer dominance. After a gap higher at the open, the price surged with high intraday volatility and stays near session highs, but overbought readings are emerging as a potential flag for a pullback.

Sideways move likely as strong momentum reduces downside risk

Over the next five trading days, LLY is likely to consolidate within a volatility band between $1,100 and $1,170. The most probable scenario is a sideways to slightly higher move within this range, with the potential for further gains above $1,170 if strong buying persists. Alternatively, a decline below $1,100 could trigger a corrective move toward immediate support at the Kijun level, but such a scenario currently has a low probability given prevailing momentum.

Anton Kharitonov, expert at Traders Union, views LLY’s breakout as driven by news momentum and technical strength, but he remains cautious. He notes heavy overbought signals and sees the risk of a near-term pullback if $1,100 does not hold. Analyst highlights that while clinical progress and R&D expansion are supporting sentiment, elevated price levels call for prudence. "Until the price consolidates above $1,100 with healthier indicators, I prefer to wait for confirmation before positioning long."

Previously it was reported that Eli Lilly’s expanding pipeline strategic acquisitions, and sustained technical strength were driving continued bullish sentiment for the stock. The latest combination of positive clinical trial news, accelerating R&D moves, and strong price action further strengthens this outlook, with investors now watching for potential consolidation or a breakout above $1,170 as the next key catalyst.

Source of Data: LLY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.